Nuvectis Pharma establishes new $200M ATM offering program with Jefferies

Nuvectis Pharma, Inc.

Entered Open Market Sale Agreement with Jefferies LLC on Aug 21, 2026, for up to $200M in common stock.
Sales made via new Form S-3 shelf registration filed Aug 21, 2026; Jefferies fee up to 3.0% of gross proceeds.
Prior ATM program terminated July 20, 2026; no further sales under the Feb 13, 2026 prospectus supplement.
No minimum sales required; proceeds used for general corporate purposes, if any shares are sold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.